MannKind (NASDAQ:MNKD) and Monte Rosa Therapeutics (NASDAQ:GLUE) Head-To-Head Analysis

Monte Rosa Therapeutics (NASDAQ:GLUE) and MannKind (NASDAQ:MNKD) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Profitability

This table compares Monte Rosa Therapeutics and MannKind’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
MannKind	-11.08%	N/A	-6.31%

Risk and Volatility

Monte Rosa Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the S&P 500. Comparatively, MannKind has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Institutional and Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 49.5% of MannKind shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Monte Rosa Therapeutics and MannKind”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$28.73 million	33.32	-$38.63 million	($1.76)	-6.38
MannKind	$348.97 million	2.81	$5.86 million	($0.13)	-23.46

MannKind has higher revenue and earnings than Monte Rosa Therapeutics. MannKind is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for Monte Rosa Therapeutics and MannKind, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	2	8	1	2.75
MannKind	1	2	8	0	2.64

Monte Rosa Therapeutics presently has a consensus target price of $26.67, suggesting a potential upside of 137.67%. MannKind has a consensus target price of $8.08, suggesting a potential upside of 165.03%. Given MannKind’s higher probable upside, analysts plainly believe MannKind is more favorable than Monte Rosa Therapeutics.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About MannKind

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.